Evaluating the Unmet Clinical Need & Limitations of Therapeutics Targeting Angiogenesis-Driven Diseases, Neovascular/wet Age-Related Macular Degeneration (AMD) & Diabetic Macular Edema (DME)

Time: 8:15 am
day: Day One


  • VEGF agents—Bevacizumab, Ranibizumab, Brolucizumab and Aflibercept—now represent the standard of care. However, despite their proven efficacy, anti-VEGF agents still face issues such as high treatment burden due to their short duration of action
  • This session will asses the treatment burden of existing therapies and other limitations. As well as an in-depth evaluation of the novel pharmacological approaches being investigated to improve efficacy and durability compared to the current standard of care